Sandoz to pay $275 million to settle drug price-fixing case
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
Sandoz Family to Get $2.9 Billion From Offloading Part of Its Novartis Stake
ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling ...
Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company") today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for the ...
Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...
Sandoz Family Pares Novartis Stake With $2.9 Billion Sale
Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...
STAT7d
J&J sues Samsung over a contract breach for a Stelara biosimilar
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...
Sandoz Group Ltd (SDZXF) Receives a Hold from UBS
In a report released today, Harry Sephton from UBS maintained a Hold rating on Sandoz Group Ltd (SDZXF – Research Report), with a price target ...
Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications
Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...
Reuters5d
Sandoz family to get $2.9 billion from offloading part of its Novartis stake
ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...
Avecho Biotechnology: Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in AustraliaAvecho ...